These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16188134)

  • 1. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
    Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
    Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
    Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
    Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
    Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
    Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
    Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
    Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
    Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
    Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
    Khurram N; Anis T; Yusuf NW
    J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
    Ang PP; Tan GC; Karim N; Wong YP
    Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
    Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F
    Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
    Bassarova AV; Nesland JM; Davidson B
    Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
    Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
    Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions.
    He DN; Zhu HS; Zhang KH; Jin WJ; Zhu WM; Li N; Li JS
    World J Gastroenterol; 2004 Aug; 10(16):2406-8. PubMed ID: 15285029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant effusions: from diagnosis to biology.
    Davidson B
    Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions.
    Ensani F; Nematizadeh F; Irvanlou G
    Pol J Pathol; 2011; 62(2):95-100. PubMed ID: 21866465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.